Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep is in a strong position with a diversified product portfolio that caters to both cancer and autoimmune disease treatments. With efti showing promising results in Phase 3 trials and multiple partnerships for its development, the company has a strong potential for growth in the long term. Additionally, the company's collaborations and partnerships demonstrate their ability to leverage their product portfolio and maximize the potential of efti in different markets, further contributing to their potential success in the future. The company's strong patent portfolio and manufacturing partnership also provide stability and potential for competitive advantage in the market.

Bears say

Immutep is facing a high level of risk due to its focus on a single drug, efti, and its reliance on a single Phase three clinical trial for marketing approval in first-line NSCLC treatment. Additionally, the company's other product candidates are still in early development stages, and their potential for success is uncertain at this time. Immutep also faces competition from other established companies in the immunotherapy space, which could impact market penetration and commercial success. These factors, combined with the regulatory uncertainty, lead to a negative outlook on Immutep's stock.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.